Kidney Cancer Drugs Market Set to Reach $10.82 Billion by 2030, Led by Pfizer, Novartis, and Exelixis

The global kidney cancer drugs market is expected to grow from $8.53 billion in 2025 to $10.82 billion by 2030, with a CAGR of 5.1%. The market's growth is attributed to advancements in targeted therapies, increasing R&D investments, progress in genomics, and the integration of AI in drug discovery. Emerging trends include the development of targeted therapies, expansion of immunotherapies, research on angiogenesis inhibition, and combination therapy strategies. Major players in the market include Pfizer, Novartis, Exelixis, Roche, Bristol Myers Squibb Company, and Bayer.